A Molecular Mechanism for Direct Sirtuin Activation by Resveratrol

PLoS ONE

Volumn 7, Issue 11, 2012, Pages

  Gertz, Melanie ^a   Nguyen, Giang Thi Tuyet ^a   Fischer, Frank ^a   Suenkel, Benjamin ^a   Schlicker, Christine ^b   Fränzel, Benjamin ^b   Tomaschewski, Jana ^b   Aladini, Firouzeh ^c   Becker, Christian ^c   Wolters, Dirk ^b   Steegborn, Clemens ^a  

^a UNIVERSITY OF BAYREUTH   (Germany)

^b RUHR UNIVERSITY BOCHUM   (Germany)

^c UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

PICEATANNOL; RESVERATROL; SIRTUIN 1; SIRTUIN 2; SIRTUIN 3; SIRTUIN 5;

ARTICLE; CONTROLLED STUDY; DRUG STRUCTURE; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME SUBSTRATE; HUMAN; MOLECULAR DYNAMICS; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INTERACTION; PROTEIN MODIFICATION; PROTEIN STRUCTURE; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS;

ACETYLATION; CALORIC RESTRICTION; CRYSTALLOGRAPHY, X-RAY; HUMANS; PEPTIDES; PROTEIN BINDING; PROTEIN CONFORMATION; SIRTUIN 1; SIRTUIN 3; SIRTUINS; STILBENES; SUBSTRATE SPECIFICITY;

EID: 84869816787     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0049761     Document Type: Article

References (62)

1. Sauve AA, Wolberger C, Schramm VL, Boeke JD, (2006) The biochemistry of sirtuins. Annu Rev Biochem 75: 435-465.
2. Guarente L, Picard F, (2005) Calorie restriction- the SIR2 connection. Cell 120: 473-482.
3. Guarente L, (2006) Sirtuins as potential targets for metabolic syndrome. Nature 444: 868-874.
4. Milne JC, Denu JM, (2008) The Sirtuin family: therapeutic targets to treat diseases of aging. Curr Opin Chem Biol 12: 11-17.
5. Michan S, Sinclair D, (2007) Sirtuins in mammals: insights into their biological function. Biochem J 404: 1-13.
6. Cohen HY, Miller C, Bitterman KJ, Wall NR, Hekking B, et al. (2004) Calorie restriction promotes mammalian cell survival by inducing the SIRT1 deacetylase. Science 305: 390-392.
7. Mostoslavsky R, Chua KF, Lombard DB, Pang WW, Fischer MR, et al. (2006) Genomic instability and aging-like phenotype in the absence of mammalian SIRT6. Cell 124: 315-329.
8. Kanfi Y, Naiman S, Amir G, Peshti V, Zinman G, et al. (2012) The sirtuin SIRT6 regulates lifespan in male mice. Nature 483: 218-221.
9. Michishita E, Park JY, Burneskis JM, Barrett JC, Horikawa I, (2005) Evolutionarily conserved and nonconserved cellular localizations and functions of human SIRT proteins. Mol Biol Cell 16: 4623-4635.
10. Rose G, Dato S, Altomare K, Bellizzi D, Garasto S, et al. (2003) Variability of the SIRT3 gene, human silent information regulator Sir2 homologue, and survivorship in the elderly. Exp Gerontol 38: 1065-1070.
11. Ahn BH, Kim HS, Song S, Lee IH, Liu J, et al. (2008) A role for the mitochondrial deacetylase Sirt3 in regulating energy homeostasis. Proc Natl Acad Sci USA 105: 14447-14452.
12. Schlicker C, Gertz M, Papatheodorou P, Kachholz B, Becker CF, et al. (2008) Substrates and regulation mechanisms for the human mitochondrial sirtuins Sirt3 and Sirt5. J Mol Biol 382: 790-801.
13. Hirschey MD, Shimazu T, Goetzman E, Jing E, Schwer B, et al. (2010) SIRT3 regulates mitochondrial fatty-acid oxidation by reversible enzyme deacetylation. Nature 464: 121-125.
14. Mahlknecht U, Ho AD, Letzel S, Voelter-Mahlknecht S, (2006) Assignment of the NAD-dependent deacetylase sirtuin 5 gene (SIRT5) to human chromosome band 6p23 by in situ hybridization. Cytogenet Genome Res 112: 208-212.
15. Nakagawa T, Lomb DJ, Haigis MC, Guarente L, (2009) SIRT5 Deacetylates carbamoyl phosphate synthetase 1 and regulates the urea cycle. Cell 137: 560-570.
16. Gertz M, Steegborn C, (2009) Function and regulation of the mitochondrial Sirtuin isoform Sirt5 in Mammalia. Biochim Biophys Acta 1804: 1658-1665.
17. Du J, Zhou Y, Su X, Yu JJ, Khan S, et al. (2011) Sirt5 is a NAD-dependent protein lysine demalonylase and desuccinylase. Science 334: 806-809.
18. Sanders BD, Jackson B, Marmorstein R, (2010) Structural basis for sirtuin function: What we know and what we don't. Biochim Biophys Acta 1804: 1604-1616.
19. Neugebauer RC, Sippl W, Jung M, (2008) Inhibitors of NAD+ dependent histone deacetylases (sirtuins). Curr Pharm Des 14: 562-573.
20. Cen Y, (2010) Sirtuins inhibitors: The approach to affinity and selectivity. Biochim Biophys Acta 1804: 1635-1644.
21. Schlicker C, Boanca G, Lakshminarasimhan M, Steegborn C, (2011) Structure-based development of novel sirtuin inhibitors. Aging (Albany NY) 3: 852-872.
22. Sauve AA, Moir RD, Schramm VL, Willis IM, (2005) Chemical activation of Sir2-dependent silencing by relief of nicotinamide inhibition. Mol Cell 17: 595-601.
23. Howitz KT, Bitterman KJ, Cohen HY, Lamming DW, Lavu S, et al. (2003) Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan. Nature 425: 191-196.
24. Milne JC, Lambert PD, Schenk S, Carney DP, Smith JJ, et al. (2007) Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes. Nature 450: 712-716.
25. Barger JL, Kayo T, Vann JM, Arias EB, Wang J, et al. (2008) A low dose of dietary resveratrol partially mimics caloric restriction and retards aging parameters in mice. PLoS ONE 3: e2264.
26. Wood JG, Rogina B, Lavu S, Howitz K, Helfand SL, et al. (2004) Sirtuin activators mimic caloric restriction and delay ageing in metazoans. Nature 430: 686-689.
27. Baur JA, Sinclair DA, (2006) Therapeutic potential of resveratrol: the in vivo evidence. Nat Rev Drug Discov 5: 493-506.
28. Baur JA, Pearson KJ, Price NL, Jamieson HA, Lerin C, et al. (2006) Resveratrol improves health and survival of mice on a high-calorie diet. Nature 444: 337-342.
29. Lagouge M, Argmann C, Gerhart-Hines Z, Meziane H, Lerin C, et al. (2006) Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1alpha. Cell 127: 1109-1122.
30. Pirola L, Frojdo S, (2008) Resveratrol: one molecule, many targets. IUBMB Life 60: 323-332.
31. Pacholec M, Bleasdale JE, Chrunyk B, Cunningham D, Flynn D, et al. (2010) SRT1720, SRT2183, SRT1460, and resveratrol are not direct activators of SIRT1. J Biol Chem 285: 8340-8351.
32. Park SJ, Ahmad F, Philp A, Baar K, Williams T, et al. (2012) Resveratrol ameliorates aging-related metabolic phenotypes by inhibiting cAMP phosphodiesterases. Cell 148: 421-433.
33. Moniot S, Weyand M, Steegborn C, (2012) Structures, substrates, and regulators of Mammalian sirtuins- opportunities and challenges for drug development. Front Pharmacol 3: 16.
34. Borra MT, Smith BC, Denu JM, (2005) Mechanism of human SIRT1 activation by resveratrol. J Biol Chem 280: 17187-17195.
35. Kaeberlein M, McDonagh T, Heltweg B, Hixon J, Westman EA, et al. (2005) Substrate-specific activation of sirtuins by resveratrol. J Biol Chem 280: 17038-17045.
36. Yang H, Baur JA, Chen A, Miller C, Adams JK, et al. (2007) Design and synthesis of compounds that extend yeast replicative lifespan. Aging Cell 6: 35-43.
37. Hoff KG, Avalos JL, Sens K, Wolberger C, (2006) Insights into the sirtuin mechanism from ternary complexes containing NAD+ and acetylated peptide. Structure 14: 1231-1240.
38. Cosgrove MS, Bever K, Avalos JL, Muhammad S, Zhang X, et al. (2006) The structural basis of sirtuin substrate affinity. Biochemistry 45: 7511-7521.
39. Dudley JI, Lekli I, Mukherjee S, Das M, Bertelli AA, et al. (2008) Does white wine qualify for French paradox? Comparison of the cardioprotective effects of red and white wines and their constituents: resveratrol, tyrosol, and hydroxytyrosol. J Agric Food Chem 56: 9362-9373.
40. Fischer F, Gertz M, Suenkel B, Lakshminarasimhan M, Schutkowski M, et al. (2012) Sirt5 deacylation activities show differential sensitivities to nicotinamide inhibition. PLoS ONE 7: e45098.
41. Dai H, Kustigian L, Carney D, Case A, Considine T, et al. (2010) SIRT1 activation by small molecules: kinetic and biophysical evidence for direct interaction of enzyme and activator. J Biol Chem 285: 32695-32703.
42. Schuetz A, Min J, Antoshenko T, Wang CL, Allali-Hassani A, et al. (2007) Structural basis of inhibition of the human NAD+-dependent deacetylase SIRT5 by suramin. Structure 15: 377-389.
43. Jin L, Wei W, Jiang Y, Peng H, Cai J, et al. (2009) Crystal structures of human SIRT3 displaying substrate-induced conformational changes. J Biol Chem 284: 24394-24405.
44. Finnin MS, Donigian JR, Pavletich NP, (2001) Structure of the histone deacetylase SIRT2. Nat Struct Biol 8: 621-625.
45. Zhao K, Harshaw R, Chai X, Marmorstein R, (2004) Structural basis for nicotinamide cleavage and ADP-ribose transfer by NAD(+)-dependent Sir2 histone/protein deacetylases. Proc Natl Acad Sci USA 101: 8563-8568.
46. Sanders BD, Zhao K, Slama JT, Marmorstein R, (2007) Structural basis for nicotinamide inhibition and base exchange in Sir2 enzymes. Mol Cell 25: 463-472.
47. Trapp J, Jochum A, Meier R, Saunders L, Marshall B, et al. (2006) Adenosine mimetics as inhibitors of NAD+-dependent histone deacetylases, from kinase to sirtuin inhibition. J Med Chem 49: 7307-7316.
48. Viswanathan M, Kim SK, Berdichevsky A, Guarente L, (2005) A role for SIR-2.1 regulation of ER stress response genes in determining C. elegans life span. Dev Cell 9: 605-615.
49. Kabsch W, (1993) Automatic processing of rotation diffraction data from crystals of initially unknown symmetry and cell constants. J Appl Cryst 26: 795-800.
50. Vaguine AA, Richelle J, Wodak SJ, (1999) SFCHECK: a unified set of procedures for evaluating the quality of macromolecular structure-factor data and their agreement with the atomic model. Acta Crystallogr D Biol Crystallogr 55: 191-205.
51. Adams PD, Grosse-Kunstleve RW, Hung LW, Ioerger TR, McCoy AJ, et al. (2002) PHENIX: building new software for automated crystallographic structure determination. Acta Crystallogr D Biol Crystallogr 58: 1948-1954.
52. Collaborative Computational Project N (1994) The CCP4 suite: programs for protein crystallography. Acta Crystallogr D Biol Crystallogr 50: 760-763.
53. Murshudov GN, Vagin AA, Dodson EJ, (1997) Refinement of macromolecular structures by the maximum-likelihood method. Acta Crystallogr D Biol Crystallogr 53: 240-255.
54. Yeates TO, (1997) Detecting and overcoming crystal twinning. Methods Enzymol 276: 344-358.
55. Vagin AA, Isupov MN, (2001) Spherically averaged phased translation function and its application to the search for molecules and fragments in electron-density maps. Acta Crystallogr D Biol Crystallogr 57: 1451-1456.
56. McCoy AJ, Grosse-Kunstleve RW, Storoni LC, Read RJ, (2005) Likelihood-enhanced fast translation functions. Acta Crystallogr D Biol Crystallogr 61: 458-464.
57. Emsley P, Cowtan K, (2004) Coot: Model-Building Tools for Molecular Graphics. Acta Cryst Section D 60: 2126-2132.
58. Schuttelkopf AW, van Aalten DM, (2004) PRODRG: a tool for high-throughput crystallography of protein-ligand complexes. Acta Crystallogr D Biol Crystallogr 60: 1355-1363.
59. Heltweg B, Dequiedt F, Verdin E, Jung M, (2003) Nonisotopic substrate for assaying both human zinc and NAD+-dependent histone deacetylases. Anal Biochem 319: 42-48.
60. Laskowski RA, Moss DS, Thornton JM, (1993) Main-chain bond lengths and bond angles in protein structures. J Mol Biol 231: 1049-1067.
61. Sanner MF, (1999) Python: a programming language for software integration and development. J Mol Graph Model 17: 57-61.
62. Diederichs K, Karplus PA, (1997) Improved R-factors for diffraction data analysis in macromolecular crystallography. Nat Struct Biol 4: 269-275.